The analysis by US biotech Circular Genomics focuses on an assay that looks for a circular RNA (circRNA) blood biomarker that the company says can predict response to sertraline, a commonly prescribed SSRI, and potentially other drugs in the class.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,